Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results
MWN-AI** Summary
Rafael Holdings, Inc. (NYSE: RFL) reported its financial results for the first quarter of fiscal year 2026, ending on October 31, 2025. The company holds a pivotal position in the biotechnology industry, focusing on pharmaceuticals and medical devices. CEO Howard Jonas expressed satisfaction with the progress of the Phase 3 TransportNPC™ study for Trappsol® Cyclo™, aimed at treating Niemann-Pick Disease Type C1. Following a review by the Data Monitoring Committee, the study will continue, reinforcing the company’s belief in Trappsol® Cyclo™ as a potential treatment for this rare genetic disorder.
Financially, Rafael Holdings reported a net loss of $9.8 million or $0.19 per share for the quarter, slightly increasing from a loss of $9.0 million or $0.37 per share year-over-year. The rise in net losses was attributed to the consolidation of expenses from Cyclo Therapeutics, acquired in March 2025. Research and development (R&D) expenses surged to $7.5 million compared to $1.3 million in the previous year, largely due to the additional expenditures associated with Cyclo.
The company had cash and cash equivalents totaling $45.5 million as of the end of the quarter, down from $52.8 million at the end of the previous fiscal year. General and administrative expenses also saw a slight increase, totaling $2.8 million, reflecting the ongoing costs from the acquired entity.
Looking ahead, Rafael Holdings emphasized the potential of its drug pipeline and reiterated its commitment to developing innovative therapies. The release highlighted both the challenges and the opportunities within the biotechnology field, pointing to the significant risks involved as the company navigates its ongoing research and clinical trials.
MWN-AI** Analysis
Rafael Holdings, Inc. (NYSE: RFL) has released its financial results for Q1 Fiscal 2026, revealing a net loss of $9.8 million, or $0.19 per share, a slight increase from the $9.0 million loss reported in the same period last year. This rise in net loss can largely be attributed to the consolidation of expenses from Cyclo Therapeutics following its acquisition earlier this year. While the elevated research and development expenses, rising from $1.3 million to $7.5 million, reflect their commitment to advancing their pipeline, investors should cautiously interpret these figures.
Despite the increased losses, the continuation of the Phase 3 TransportNPC™ trial of the Trappsol® Cyclo™ product for Niemann-Pick Disease Type C1 is a bright spot. The Data Monitoring Committee's recommendation to proceed suggests that the therapy is on a promising path. If the clinical results continue to uphold safety and efficacy, Rafael could be at the precipice of a significant breakthrough in treating this rare genetic disorder.
However, investors should be aware of the company's cash position, now at $45.5 million, a decrease from prior quarters. With a substantial portion of its capital directed towards R&D, close attention should be paid to how effectively these funds are utilized, particularly as losses widen.
The financial indicators from the balance sheet also show increasing liabilities, which can pose a risk in terms of financial flexibility. Overall, while seeking investment in Rafael Holdings carries inherent risks associated with biotech ventures—particularly in early-stage clinical trials—the potential upside from a successful product launch could be considerable. Investors should weigh the current loss against the long-term promise of Trappsol® Cyclo™ while keeping an eye on future financial liquidity and progress in clinical trials. Caution is advised for risk-averse investors until clearer signs of profitability emerge.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025.
“We remain pleased with the progress of our pivotal Phase 3 TransportNPC ™ study evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol ® Cyclo™ could provide an important new treatment option for patients suffering from this rare and fatal genetic disease,” said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings.
Rafael Holdings, Inc. First Quarter Fiscal Year 2026 Financial Results
As of October 31, 2025, we had cash and cash equivalents of $45.5 million.
For the three months ended October 31, 2025, we recorded a net loss attributable to Rafael Holdings of $9.8 million, or $0.19 per share, versus a net loss of $9.0 million, or $0.37 per share in the year ago period. The year over year increase in net loss is attributable to the consolidation of Cyclo Therapeutic’s expenses following the acquisition of Cyclo in March 2025.
Research and development expenses were $7.5 million for the three months ended October 31, 2025, compared to $1.3 million in the year ago period. The year over year increase relates to the inclusion in the current year period of spending at Cyclo following the March 2025 acquisition.
General and administrative expenses were $2.8 million for the three months ended October 31, 2025, compared to $2.5 million in the year ago period. The year over year increase relates to the inclusion of expenses at Cyclo following the March 2025 acquisition .
About Rafael Holdings, Inc.
Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early stage companies that develop pharmaceuticals and medical devices. Our lead candidate is Trappsol® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (“NPC1”), a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company. Our lead candidate, Trappsol® Cyclo™, is the subject of an ongoing pivotal Phase 3 clinical trial.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended July 31, 2024, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Contact:
Barbara Ryan
Barbara.ryan@rafaelholdings.com
(203) 274-2825
| RAFAEL HOLDINGS, INC. | ||||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||||
| (in thousands, except share and per share data) | ||||||||||
| October 31, 2025 | July 31, 2025 | |||||||||
| (unaudited) | ||||||||||
| ASSETS | ||||||||||
| CURRENT ASSETS | ||||||||||
| Cash and cash equivalents | $ | 45,539 | $ | 52,769 | ||||||
| Prepaid clinical costs | 1,584 | 1,045 | ||||||||
| Other receivables | — | 1,206 | ||||||||
| Accounts receivable, net of allowance for credit losses of $245 at October 31, 2025 and July 31, 2025 | 413 | 627 | ||||||||
| Inventory | 272 | 281 | ||||||||
| Prepaid expenses and other current assets | 513 | 786 | ||||||||
| Total current assets | 48,321 | 56,714 | ||||||||
| Property and equipment, net | 1,562 | 1,596 | ||||||||
| Non-current prepaid clinical costs | 629 | 1,399 | ||||||||
| Convertible notes receivable classified as available-for-sale | 1,858 | 1,858 | ||||||||
| Goodwill | 19,939 | 19,939 | ||||||||
| Intangible assets, net | 962 | 994 | ||||||||
| In-process research and development | 31,575 | 31,575 | ||||||||
| Investments | 500 | — | ||||||||
| Other assets | 29 | 34 | ||||||||
| TOTAL ASSETS | $ | 105,375 | $ | 114,109 | ||||||
| LIABILITIES AND EQUITY | ||||||||||
| CURRENT LIABILITIES | ||||||||||
| Accounts payable | $ | 6,794 | $ | 6,893 | ||||||
| Accrued expenses | 3,860 | 3,304 | ||||||||
| Convertible notes payable | 608 | 614 | ||||||||
| Due to related parties | 751 | 723 | ||||||||
| Other current liabilities | 63 | 66 | ||||||||
| Total current liabilities | 12,076 | 11,600 | ||||||||
| Accrued expenses, noncurrent | ||||||||||
| Convertible notes payable, noncurrent | 3,898 | 3,895 | ||||||||
| Deferred income tax liability | 56 | 78 | ||||||||
| Other liabilities | 138 | 138 | ||||||||
| TOTAL LIABILITIES | 27 | 27 | ||||||||
| 16,195 | 15,738 | |||||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||||
| EQUITY | ||||||||||
| Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of October 31, 2025 and July 31, 2025 | 8 | 8 | ||||||||
| Class B common stock, $0.01 par value; 200,000,000 shares authorized, 50,867,964 issued and outstanding (excluding treasury shares of 101,487) as of October 31, 2025, and 50,789,697 issued and outstanding (excluding treasury shares of 101,487) as of July 31, 2025 | 509 | 508 | ||||||||
| Additional paid-in capital | 322,730 | 322,161 | ||||||||
| Accumulated deficit | (242,079 | ) | (232,263 | ) | ||||||
| Treasury stock, at cost; 101,487 Class B shares as of October 31, 2025 and July 31, 2025 | (168 | ) | (168 | ) | ||||||
| Accumulated other comprehensive income related to unrealized income on available-for-sale securities | 358 | 358 | ||||||||
| Accumulated other comprehensive income related to foreign currency translation adjustment | 3,823 | 3,787 | ||||||||
| Total equity attributable to Rafael Holdings, Inc. | 85,181 | 94,391 | ||||||||
| Noncontrolling interests | 3,999 | 3,980 | ||||||||
| TOTAL EQUITY | 89,180 | 98,371 | ||||||||
| TOTAL LIABILITIES AND EQUITY | $ | 105,375 | $ | 114,109 | ||||||
| RAFAEL HOLDINGS, INC. | |||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||||||||
| (unaudited, in thousands, except share and per share data) | |||||||||
| Three Months Ended October 31, | |||||||||
| 2025 | 2024 | ||||||||
| Revenues | $ | 240 | $ | 128 | |||||
| Cost of infusion Technology revenue | - | 37 | |||||||
| Cost of product revenue | 9 | - | |||||||
| SG&A Expenses | 2,838 | 2,523 | |||||||
| R&D Expenses | 7,484 | 1,326 | |||||||
| Depreciation and amortization | 50 | 86 | |||||||
| Operating Loss | (10,141 | ) | (3,844 | ) | |||||
| Interest income | 399 | 568 | |||||||
| Realized gain on available-for-sale securities | - | 194 | |||||||
| Unrealized loss on investments - Cyclo Therapeutics Inc. | - | (4,365 | ) | ||||||
| Unrealized loss on convertible notes receivable, due from Cyclo | - | (1,588 | ) | ||||||
| Interest expense | (160 | ) | (162 | ) | |||||
| Other income (loss) | 115 | (2 | ) | ||||||
| Loss before Incomes Taxes | (9,787 | ) | (9,199 | ) | |||||
| Taxes | (10 | ) | (12 | ) | |||||
| Consolidated net loss | (9,797 | ) | (9,211 | ) | |||||
| Net income (loss) attributable to noncontrolling interests | 19 | (205 | ) | ||||||
| Net loss attributable to Rafael Holdings, Inc. | $ | (9,816 | ) | $ | (9,006 | ) | |||
| Continuing operations loss per share | |||||||||
| Net loss from operations | (9,797 | ) | (9,211 | ) | |||||
| Net income (loss) attributable to noncontrolling interests | 19 | (205 | ) | ||||||
| Numerator for loss per share from operations | $ | (9,816 | ) | $ | (9,006 | ) | |||
| Loss per share | |||||||||
| Basic and diluted | (0.19 | ) | (0.37 | ) | |||||
| Loss per basic common share | $ | (0.19 | ) | $ | (0.37 | ) | |||
| Weighted average shares in calculation | 51,184,407 | 24,062,854 | |||||||
FAQ**
What are the long-term financial implications of Rafael Holdings Inc. Class B RFL's net loss increasing to $9.8 million this quarter compared to $9.0 million in the previous year, and how might this affect investor confidence?
How does the ongoing Phase 3 TransportNPC study for Trappsol® Cyclo™ position Rafael Holdings Inc. Class B RFL in the competitive landscape of treatments for Niemann-Pick Disease Type C1, particularly concerning regulatory approvals?
Given the substantial increase in R&D expenses to $7.5 million due to the integration of Cyclo Therapeutics, how does Rafael Holdings Inc. Class B RFL plan to balance these costs with its financial runway, especially considering its cash reserves of $45.5 million?
What are the expected milestones for Rafael Holdings Inc. Class B RFL in the next quarter, particularly in relation to the Phase 3 study and its potential impact on future revenue generation?
**MWN-AI FAQ is based on asking OpenAI questions about Rafael Holdings Inc. Class B (NYSE: RFL).
NASDAQ: RFL
RFL Trading
0.0% G/L:
$1.50 Last:
28,910 Volume:
$1.47 Open:
